TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05570097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intercostal nerves cryoanalgesia
Description: Intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
Study: NCT05682703

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
Study: NCT05599659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team.~The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans.~The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant.
Study: NCT04229043

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink
Description: Drink that will be ingested

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink
Description: Drink that will be ingested

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Drink that will be ingested

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Drink that will be ingested
Study: NCT05911217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT041 autologous CAR T-cell injection
Description: Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
Study: NCT05637502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
Study: NCT04119934

Intervention type: BEHAVIORAL
Intervention: Smoking Cessation Intervention Tool
Description: A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
Study: NCT05905432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine AnAPN1
Description: AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine AnAPN1
Description: AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine AnAPN1
Description: AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
Study: NCT06213116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MADgic Atomizer
Description: Device to deliver directly lignocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine pump spray
Description: Lignocaine 30 mg (3 puffs) given via 10mg Lignocaine Pump Spray prior to endotracheal intubation
Study: NCT06251804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exercise program
Description: The exercise program includes a short foot exercise and will be given in water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based-program
Description: The exercise program includes a short foot exercise and will be given on land.
Study: NCT04745117

Intervention type: BEHAVIORAL
Intervention: READHY - questionnaire
Description: The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
Study: NCT06427499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: brush 2 min morning \& night daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: brush 2 min morning \& night daily
Study: NCT06294288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 1 (Single)
Description: A single dose of LP-003 (Dose 1) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 2 (Single)
Description: A single dose of LP-003 (Dose 2) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 3 (Single)
Description: A single dose of LP-003 (Dose 3) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 4 (Single)
Description: A single dose of LP-003 (Dose 4) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 5 (Single)
Description: A single dose of LP-003 (Dose 5) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Single)
Description: A single dose of placebo was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 6 (Multiple)
Description: LP-003 (Dose 6) was administered multiple times subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 7 (Multiple)
Description: LP-003 (Dose 7) was administered multiple times subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 Dose 8 (Multiple)
Description: LP-003 (Dose 8) was administered multiple times subcutaneously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Multiple)
Description: Placebo was administered multiple times subcutaneously.
Study: NCT04740307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
Study: NCT04258072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
Study: NCT05328960

Intervention type: OTHER
Intervention: Diagnosed during or not during the pandemic
Description: We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
Study: NCT04997304

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AirDuo Digihaler
Description: Patients will receive the AirDuo® Digihaler™ at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ProAir Digihaler
Description: Patients will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
Study: NCT05716347

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Description: one booster dose intramuscularly in the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Description: one booster dose intramuscularly in the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Description: one booster dose intramuscularly in the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Description: one booster dose intramuscularly in the deltoid muscle of the upper arm.
Study: NCT04724135

Intervention type: OTHER
Intervention: Survey
Description: The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
Study: NCT05944640

Intervention type: PROCEDURE
Intervention: Intraocular surgery
Description: Pars plana vitrectomy or cataract surgery.

Intervention type: PROCEDURE
Intervention: Intraocular surgery
Description: Pars plana vitrectomy or cataract surgery.

Intervention type: PROCEDURE
Intervention: Intraocular surgery
Description: Pars plana vitrectomy or cataract surgery.
Study: NCT05074329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moventis PNS
Description: Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Moventis PNS
Description: Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
Study: NCT06349876

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: slandered laparoscopic cholecystectomy
Study: NCT04773275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electric field treatment using the Aliya system
Description: Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
Study: NCT04580927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy (BSE)
Description: Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
Study: NCT04819776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Oral iloperidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iloperidone Placebo
Description: Oral placebo
Study: NCT05657652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine, cytarabine,venetoclax
Description: Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
Study: NCT05174936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLWH intervention
Description: The intervention curriculum will consist of five interactive training sessions (2 hours each) with four specific areas of resilience-building: individual assets (self-esteem, emotion regulation, positive future orientation), coping with infection/illness (medical adherence, stress reduction, healthy lifestyle, self-care), relationship building (family relationship, provider-patient relationship), and social support (identifying and seeking social support at various socioecological levels).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family member intervention
Description: The intervention will consist of five sessions of group activities (2 hours each), with each session addressing one or more of the following areas: 1) HIV and ART knowledge; 2) support to strengthen the capacity of PLWH and their family members to adapt to living with HIV; 3) relationship building (family relationships, intimate relationships); 4) emotional and behavioral support for PLWH's adherence to care and treatment, including tailored coping or support strategies to address unique needs of some participants who may be more prone to HIV stigma (e.g., MSM and their family members); and 5) self-care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare provider intervention
Description: The HCP intervention will adapt Popular Opinion Leaders (POL) principles by teaching participants skills for initiating/disseminating stigma reduction messages/practices to colleagues in the workplace. The HCP intervention will consist of four 1.5-hour sessions addressing the following topics: 1) universal HIV precautions and occupational safety (e.g., correctly knowing and practicing universal precautions and decreasing fear of PLWH); 2) intersecting stigma against PLWH (e.g., manifestations of intersecting stigma in clinical settings); 3) provider-patient relationship (e.g., reducing stigmatizing attitudes and behaviors toward PLWH, respecting patients' rights for privacy related to care and disclosure); 4) improving quality of patient care (e.g., increasing skills and comfort in working with PLWH); 5) building a supportive medical environment for better care of PLWH; and 6) skills and confidence in delivering stigma reduction messages to coworkers.
Study: NCT05003609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Rehabilitation
Description: The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
Study: NCT06267092

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment given
Description: Participants will not get any medicine during this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide and Semaglutide
Description: Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
Study: NCT04751942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-compressive Bioactive Garment
Description: patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombo-embolic deterrent
Description: patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
Study: NCT05101148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
Study: NCT05936359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Rux will be administered according to Prescribing Information/SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Rux will be administered according to Prescribing Information/SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Rux will be administered according to Prescribing Information/SmPC.
Study: NCT05822830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered SC
Study: NCT05785546

Intervention type: OTHER
Intervention: usual care
Description: For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.

Intervention type: OTHER
Intervention: usual care
Description: For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
Study: NCT05932251

Intervention type: DRUG
Intervention: Metformin
Description: All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice

Intervention type: DRUG
Intervention: Metformin
Description: All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice
Study: NCT06532617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+S-1or Capecitabine
Description: Eligible patients will receive Cadonilimab (6mg/k, iv, D1,Q3W)combined with S-1 (40-60mg po BID Q3W D1-14）or Capecitabine (1250mg/m2, po BID Q3W D1-14）until disease progression or unacceptable toxicity. Patients who had used S-1 in the first line should choose capecitabine; patients who had used capecitabine in the first line should choose S-1; otherwise decided by investigator's choice.
Study: NCT05628168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Mobilization Techniques
Description: The slider neurodynamic technique for the median nerve is conducted.Tensioner neurodynamic technique for the tibial nerve is conducted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical Therapy Program
Description: The participants only received a selected therapy program similar to the NMG with no change in duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected Physical Therapy Program
Description: The participants only received a selected therapy program similar to the NMG with no change in duration.